Medication

BioCryst to Present at Jefferies Virtual Healthcare Conference

Thursday, May 28, 2020 - 9:15pm

RESEARCH TRIANGLE PARK, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:30 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:30 a.m.
  • ET.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • For more information, please visit the Company's website at www.BioCryst.com .

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

Thursday, May 28, 2020 - 9:30pm

To access the live webcast and archived recordings for each presentation, visit theNews & Events section of the Phathom website at www.investors.phathompharma.com .

Key Points: 
  • To access the live webcast and archived recordings for each presentation, visit theNews & Events section of the Phathom website at www.investors.phathompharma.com .
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
  • Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
  • For more information about Phathom, visit the companys website at www.phathompharma.com or follow the Company on LinkedIn at www.linkedin.com/company/phathompharma .

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19

Thursday, May 28, 2020 - 9:30pm

MicroSafe Care Australia received approval for their patented and trademarked Nanocyn Disinfectant & Sanitizer, which is manufactured by Sonoma using its patented Microcyn Technology, to be entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19).

Key Points: 
  • MicroSafe Care Australia received approval for their patented and trademarked Nanocyn Disinfectant & Sanitizer, which is manufactured by Sonoma using its patented Microcyn Technology, to be entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19).
  • Claims that a disinfectant has a virucidal effect must be expressly permitted by the Australian Therapeutic Goods Administration before being used in consumer advertising (including on the label) in Australia.
  • The MicroSafe Group has operations in several international countries with its head office in Dubai, United Arab Emirates.
  • Sonoma Pharmaceuticals, Microcyn and Microdacyn60 are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Global Over-the-counter Drugs market is Expected to Reach $237.66 Billion by 2027 - Latest Market Research Report by Stratistics MRC

Thursday, May 28, 2020 - 2:39pm

GAITHERSBURG, Maryland, May 28, 2020 /PRNewswire/ -- According to Stratistics MRC, the Global Over-the-counter Drugs market is accounted for $125.00 billion in 2018 and is expected to reach $237.66 billion by 2027 growing at a CAGR of 7.4% during the forecast period.

Key Points: 
  • GAITHERSBURG, Maryland, May 28, 2020 /PRNewswire/ -- According to Stratistics MRC, the Global Over-the-counter Drugs market is accounted for $125.00 billion in 2018 and is expected to reach $237.66 billion by 2027 growing at a CAGR of 7.4% during the forecast period.
  • While the factors like the inclination of pharmaceutical companies toward OTC drugs from RX drugs and favorable regulatory framework are the factors fueling the growth of the market.
  • Over-the-counter drugs, also known as non-prescription drugs, refer to medicines that can be bought without a prescription.
  • Over-the-counter (OTC) drugs are primarily used to treat conditions that do not require direct consultation of a doctor.

SwRI Awarded $1.9 Million Contract to Develop Treatment for COVID-19 in Collaboration with DOD

Thursday, May 28, 2020 - 3:00pm

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF) has awarded SwRI a $1.9 million, one-year contract to support these efforts to identify potential COVID-19 treatments.

Key Points: 
  • The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF) has awarded SwRI a $1.9 million, one-year contract to support these efforts to identify potential COVID-19 treatments.
  • SwRI is working with the DOD High Performance Computing Modernization Program to rapidly screen potential drug compounds using SwRIs 3D drug screening software tool, Rhodium.
  • This grant will enable SwRI to collaborate to develop safe antiviral drug therapy treatment options for COVID in record time, said Dr. Joe McDonough, director of SwRIs Pharmaceutical and Bioengineering Department.
  • The Institute has previously used this process to develop drug treatment therapies for Ebola virus, malaria and other infectious diseases.

X4 Pharmaceuticals to Present at Two June Virtual Investor Conferences

Thursday, May 28, 2020 - 1:00pm

A live webcast of the presentation from both conferences will be available on the investors section of the X4 Pharmaceuticals website at www.x4pharma.com .

Key Points: 
  • A live webcast of the presentation from both conferences will be available on the investors section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcast, the event will remain archived on the X4 Pharmaceuticals website for approximately 90 days.
  • The Companys lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

Chimerix to Present at Jefferies Virtual Healthcare Conference

Thursday, May 28, 2020 - 1:00pm

DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m.

Key Points: 
  • DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m.
  • Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
  • Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).
  • Dociparstat sodium is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that may be dosed at much higher levels without triggering bleeding complications.

Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference

Thursday, May 28, 2020 - 12:01pm

LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros President and Chief Executive Officer Jasbir S. Seehra, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:00 am ET.

Key Points: 
  • LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros President and Chief Executive Officer Jasbir S. Seehra, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:00 am ET.
  • Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need.
  • Keros lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis.
  • Keros third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Blueprint Medicines to Present at Upcoming Investors Conferences

Wednesday, May 27, 2020 - 9:30pm

Virtual Goldman Sachs 41st Annual Global Healthcare Conferenceon Wednesday, June 10, 2020 at 8:50 a.m.

Key Points: 
  • Virtual Goldman Sachs 41st Annual Global Healthcare Conferenceon Wednesday, June 10, 2020 at 8:50 a.m.
  • A live webcast of each presentation will be available by visiting the Investors & Media section ofBlueprint Medicines'website at http://ir.blueprintmedicines.com .
  • Blueprint Medicines is a precision therapy company striving to improve human health.
  • We have one FDA-approved precision therapy and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs.

Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Sorrento Therapeutics, Inc. (SRNE)

Wednesday, May 27, 2020 - 9:46pm

If you purchased Sorrento securities between May 15, 2020 and May 22, 2020, inclusive (the Class Period), you are encouraged to contact Scott+Scott attorney Joe Pettigrew for additional information at (844) 818-6982 or jpettigrew@scott-scott.com .

Key Points: 
  • If you purchased Sorrento securities between May 15, 2020 and May 22, 2020, inclusive (the Class Period), you are encouraged to contact Scott+Scott attorney Joe Pettigrew for additional information at (844) 818-6982 or jpettigrew@scott-scott.com .
  • Sorrento is a biopharmaceutical company that researches human therapeutic antibodies for the treatment of cancer, inflammation, and metabolic and infectious diseases.
  • Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.
  • The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.